✦ LIBER ✦

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

✍ Scribed by Javier Cortes; Joyce O'Shaughnessy; David Loesch; Joanne L Blum; Linda T Vahdat; Katarina Petrakova; Philippe Chollet; Alexey Manikas; Veronique Diéras; Thierry Delozier; Vladimir Vladimirov; Fatima Cardoso; Han Koh; Philippe Bougnoux; Corina E Dutcus; Seth Seegobin; Denis Mir; Nicole Meneses; Jantien Wanders; Chris Twelves

Book ID: 117307977
Publisher: The Lancet
Year: 2011
Tongue: English
Weight: 392 KB
Volume: 377
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(11)60070-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase l/lI, Open-label, Randomised Stu

A Phase l/lI, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer

✍ E. Van Cutsem; H. Prenen; C. Guillen-Ponce; J. Bennouna; M. Di Benedetto; O. Bou 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Adjuvant chemotherapy and timing of tamo

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

✍ Kathy S Albain; William E Barlow; Peter M Ravdin; William B Farrar; Gary V Burto 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 145 KB

Efficacy and safety of erlotinib versus

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

✍ Tudor Ciuleanu; Lilia Stelmakh; Saulius Cicenas; Skaidrius Miliauskas; Alexandru 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 381 KB

Erlotinib versus chemotherapy as first-l

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

✍ Caicun Zhou; Yi-Long Wu; Gongyan Chen; Jifeng Feng; Xiao-Qing Liu; Changli Wang; 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 265 KB

Motesanib, or open-label bevacizumab, in

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

✍ Miguel Martin; Henri Roche; Tamas Pinter; John Crown; M John Kennedy; Louise Pro 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 230 KB

2123 POSTER MO19391: an open-label safet

2123 POSTER MO19391: an open-label safety study of bevacizumab plus taxane monotherapy or in combination as first-line treatment of patients with locally recurrent or metastatic breast cancer (LR or MBC)

✍ I.E. Smith; L. Biganzoli; H. Cortes-Funes; F. Franke; Y. Mostafa Kamel; J.Y. Pie 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB